Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $30,479.04 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 1,671 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total value of $30,479.04. Following the sale, the chief executive officer now owns 575,661 shares in the company, valued at approximately $10,500,056.64. This trade represents a 0.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Saurabh Saha also recently made the following trade(s):

• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total transaction of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total transaction of $2,891,000.00.

Centessa Pharmaceuticals Trading Down 6.3 %

Shares of NASDAQ CNTA opened at $17.04 on Friday. Centessa Pharmaceuticals plc has a twelve month low of $5.58 and a twelve month high of $18.74. The firm has a market cap of $1.93 billion, a PE ratio of -11.14 and a beta of 1.47. The business has a fifty day simple moving average of $16.09 and a two-hundred day simple moving average of $12.40. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CNTA. Guggenheim boosted their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Jefferies Financial Group boosted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. B. Riley initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. Oppenheimer reissued an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $25.83.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth $330,000. EntryPoint Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter valued at about $109,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Centessa Pharmaceuticals by 16.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after buying an additional 418,615 shares in the last quarter. First Light Asset Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $33,923,000. Finally, Artal Group S.A. grew its position in shares of Centessa Pharmaceuticals by 39.5% in the 1st quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after buying an additional 400,000 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.